Hyaluronan induces vascular smooth muscle cell migration through RHAMM-mediated PI3K-dependent Rac activation

Cardiovasc Res. 2006 Nov 1;72(2):339-48. doi: 10.1016/j.cardiores.2006.07.017. Epub 2006 Jul 29.

Abstract

Objective: Hyaluronan (HA) is an important constituent of the extracellular matrix and is known to regulate cellular events through binding to CD44 and the receptor for HA-mediated motility (RHAMM). Here we investigated the role of these receptors and the signaling pathways involved in HA-mediated effects in arterial smooth muscle cells (ASMC).

Methods: Effects of high-molecular weight HA (1 to 5 mg/ml) were analyzed in cultured ASMC from rat aorta.

Results: HA promoted actin stress fiber and lamellipodia formation and dose-dependently induced ASMC migration without effect on proliferation. Pull-down assay of Rho protein activity indicated that HA activated RhoA and Rac. HA-induced ASMC migration was not affected by the RhoA inhibitor Tat-C3 (10 microg/ml), the Rho kinase inhibitor Y-27632 (10 microM) and blocking anti-CD44 antibody ,but was reduced by the non-selective Rho protein inhibitor simvastatin (10 microM), the Rac inhibitor LT-toxin (1 mug/ml), small interfering RNA (siRNA) targeting Rac and the phosphatidyl inositol 3-kinase (PI3K) inhibitor LY294002 (25 microM), which also blocked HA-induced Rac activation. CD44 knockdown by siRNA inhibited HA-mediated RhoA activation without effect on ASMC migration. In contrast, siRNA targeting RHAMM inhibited both HA-induced migration and Rac activation.

Conclusions: High-molecular weight HA independently activates RhoA and Rac through CD44 and RHAMM, respectively. HA-induced migration depends exclusively on RHAMM-mediated PI3K-dependent Rac activation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Actins / metabolism
  • Amides / pharmacology
  • Animals
  • Antibodies, Monoclonal / pharmacology
  • Aorta
  • Bacterial Toxins / pharmacology
  • Cell Movement / drug effects
  • Cells, Cultured
  • Chromones / pharmacology
  • Complement C3 / genetics
  • Cytoskeleton / metabolism
  • Dose-Response Relationship, Drug
  • Enterotoxins / pharmacology
  • Escherichia coli Proteins / pharmacology
  • Extracellular Matrix Proteins / metabolism*
  • Genes, tat
  • Hyaluronan Receptors / immunology
  • Hyaluronan Receptors / metabolism*
  • Hyaluronic Acid / pharmacology*
  • Intracellular Signaling Peptides and Proteins / antagonists & inhibitors
  • Morpholines / pharmacology
  • Muscle, Smooth, Vascular / cytology
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / metabolism*
  • Phosphatidylinositol 3-Kinases / metabolism*
  • Phosphoinositide-3 Kinase Inhibitors
  • Protein Serine-Threonine Kinases / antagonists & inhibitors
  • Pyridines / pharmacology
  • RNA Interference
  • RNA, Small Interfering / pharmacology
  • Rats
  • Recombinant Fusion Proteins / pharmacology
  • Signal Transduction
  • Simvastatin / pharmacology
  • Stimulation, Chemical
  • rac GTP-Binding Proteins / antagonists & inhibitors
  • rac GTP-Binding Proteins / genetics
  • rac GTP-Binding Proteins / metabolism
  • rho-Associated Kinases
  • rhoA GTP-Binding Protein / antagonists & inhibitors
  • rhoA GTP-Binding Protein / metabolism

Substances

  • Actins
  • Amides
  • Antibodies, Monoclonal
  • Bacterial Toxins
  • Chromones
  • Complement C3
  • Enterotoxins
  • Escherichia coli Proteins
  • Extracellular Matrix Proteins
  • Hyaluronan Receptors
  • Intracellular Signaling Peptides and Proteins
  • Morpholines
  • Phosphoinositide-3 Kinase Inhibitors
  • Pyridines
  • RNA, Small Interfering
  • Recombinant Fusion Proteins
  • hyaluronan-mediated motility receptor
  • Y 27632
  • 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
  • Hyaluronic Acid
  • Simvastatin
  • heat-labile enterotoxin, E coli
  • Protein Serine-Threonine Kinases
  • rho-Associated Kinases
  • rac GTP-Binding Proteins
  • rhoA GTP-Binding Protein